Sep 19, 2017· Comment submitted by Nathan Donley, Ph.D., Senior Scientist, Environmental Health Program, Center for Biological Diversity (CBD)· EPA-HQ-OPP-2017-0180-0020
Filed on regulations.gov — full text not in the inline record.
EPANonrulemakingEPA-HQ-OPP-2017-0180
FIFRA Scientific Advisory Panel; Notice of Public Meeting: PBPK for addressing pharmacokinetic differences between and within species
RIN
—
Last modified
Apr 16, 2024
Comment window
closed 3226d ago
Center for Biological Diversity filings
1
Activity
Center for Biological Diversity filed 1 comment on this docket between Sep 19, 2017 and Sep 19, 2017. 2 other organizations filed here. The comment window closed 3226d ago.
What Center for Biological Diversity filed (1)
Abstract
To review PBPK or PBPK-PD models and the appropriateness of their applications in human health risk assessment, including sensitive populations. In addition, to evaluate the appropriateness of using PBPK (or PBPK-PD) models for intended risk assessment purposes, such as deriving chemical-specific extrapolation factors to replace default uncertainty factors, or estimating human points of departure for various exposure scenarios (e.g., dietary, drinking water, and worker exposures).
View on regulations.gov →Co-filers (2)
See everyone who commented →- Center for Biological DiversityTHIS ORG1 filing · confidence 97%
- Dow ArgoSciences LLCunverified attribution1 filing · confidence 70%
- Oregon State University Joint Facultyunverified attribution1 filing · confidence 70%